Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
2170 articles with Johnson & Johnson Family of Companies
Sales of $20.6 billion reflecting a decline of 1.3%, operational growth of 1.6%* and adjusted operational growth of 3.7%*
Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.
XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
EINSTEIN-Jr is the largest pediatric trial conducted for the treatment of venous thromboembolism (VTE) and the first to evaluate a direct oral anticoagulant in this population
Despite Political Rhetoric, Some Drug Prices Jumped on July 1, Including Medicines on Shortage Lists
7/2/2019The beginning of July is when many companies increase the price on prescription medications in the U.S. This year's price increases are higher than the same period last year.
The sealant was developed by Grifols and combines two plasma proteins, fibrinogen and thrombin. The spray is administered with New Jersey-based Ethicon’s airless spray device.
The public’s perception of the drug industry can be confusing. Recent studies take a hard look at the industry from different perspectives.
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, July 16th, to review second-quarter results.
6/17/2019Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
A new report brings together the voices of more than 2,500 nurses and nurse-midwives from 117 different countries on the topic of gender and leadership
Hundreds lose their jobs as companies close facilities and shift business focuses.
Sharing Progress in Environmental, Social and Governance Practices
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
Johnson & Johnson Celebrates Scientists Across Generations and Geographies with 2019 Dr. Paul Janssen Award for Biomedical Research and Champions of Science® Storytelling Challenge
Franz-Ulrich Hartl and Arthur Horwich Named 2019 Dr. Paul Janssen Award Winners for Revolutionary Insights into the Fundamental Molecular Process of Protein Folding
Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
New formulation also showed shorter administration time and lower rate of infusion-related reactions
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted with DARZALEX
ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Phase 3 results featured in oral presentation at ASCO 2019, selected for Best of ASCO 2019 Meetings, and simultaneously published in The New England Journal of Medicine
U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Priority Review for the supplemental New Drug Application for INVOKANA® to reduce the risk of end-stage kidney disease, the doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Andrew Douthwaite, chief technology officer for Colorado-based VirtualArmour, a cybersecurity company, told BioSpace that biotech and pharma companies are desirable targets for hackers and cyber thieves due to the value of the intellectual property.
New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)
The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting that illustrates the value of SPRAVATO™ CIII nasal spray for treatment-resistant depression, for patients, U.S. payers, and society.
Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension
Owlstone Medical announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.